Comparative assessment of deferiprone and deferasirox in thalassemia major patients in the first two decades-single centre experience

Mathew Zachariah, Surekha Tony, Wafa Bashir, Abdulhakim Al Rawas, Yasser Wali, Anil Pathare

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Iron overload is mainly responsible for the morbidity and mortality in patients with beta thalassemia major (TM). Our aim was to compare treatment outcomes with oral iron chelators, deferiprone (DFP), and deferasirox (DFX) in the first two decades on therapy. Seventy patients with TM (mean age ± SD, 7.9 ± 4.2; range 1.5-17 years) attending the pediatric day care unit for regular transfusional support were enrolled in this cross-sectional cohort study. The patients were treated either with DFP at the dose of 75-100 mg/kg/d in three divided doses after food or DFX at the dose of 25-40 mg/kg/d as single dose before food. Mean serum ferritin (±SD) was lower in patients below 10 years (n = 44) at 1283 (±600) ng/mL when compared with patients ≥10 years (n = 19) at 1546 (±589) ng/mL. There was no significant difference in mean serum ferritin (±SD) level in patients receiving DFP (1360 ± 589) versus DFX (1260 ± 641) in this cohort, P > 0.05. 67% of the patients had Vitamin D deficiency (

Original languageEnglish
Pages (from-to)104-112
Number of pages9
JournalPediatric Hematology and Oncology
Volume30
Issue number2
DOIs
Publication statusPublished - Mar 2013

Fingerprint

beta-Thalassemia
Ferritins
Food
Vitamin D Deficiency
Iron Overload
Chelating Agents
deferiprone
deferasirox
Serum
Cohort Studies
Iron
Cross-Sectional Studies
Pediatrics
Morbidity
Mortality

Keywords

  • Beta thalassemia major
  • Deferasirox
  • Deferiprone
  • Ferritin
  • Iron overload

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

@article{71d2e937ac6949ac9e965e1e8f043c06,
title = "Comparative assessment of deferiprone and deferasirox in thalassemia major patients in the first two decades-single centre experience",
abstract = "Iron overload is mainly responsible for the morbidity and mortality in patients with beta thalassemia major (TM). Our aim was to compare treatment outcomes with oral iron chelators, deferiprone (DFP), and deferasirox (DFX) in the first two decades on therapy. Seventy patients with TM (mean age ± SD, 7.9 ± 4.2; range 1.5-17 years) attending the pediatric day care unit for regular transfusional support were enrolled in this cross-sectional cohort study. The patients were treated either with DFP at the dose of 75-100 mg/kg/d in three divided doses after food or DFX at the dose of 25-40 mg/kg/d as single dose before food. Mean serum ferritin (±SD) was lower in patients below 10 years (n = 44) at 1283 (±600) ng/mL when compared with patients ≥10 years (n = 19) at 1546 (±589) ng/mL. There was no significant difference in mean serum ferritin (±SD) level in patients receiving DFP (1360 ± 589) versus DFX (1260 ± 641) in this cohort, P > 0.05. 67{\%} of the patients had Vitamin D deficiency (",
keywords = "Beta thalassemia major, Deferasirox, Deferiprone, Ferritin, Iron overload",
author = "Mathew Zachariah and Surekha Tony and Wafa Bashir and {Al Rawas}, Abdulhakim and Yasser Wali and Anil Pathare",
year = "2013",
month = "3",
doi = "10.3109/08880018.2012.762568",
language = "English",
volume = "30",
pages = "104--112",
journal = "Pediatric Hematology and Oncology",
issn = "0888-0018",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Comparative assessment of deferiprone and deferasirox in thalassemia major patients in the first two decades-single centre experience

AU - Zachariah, Mathew

AU - Tony, Surekha

AU - Bashir, Wafa

AU - Al Rawas, Abdulhakim

AU - Wali, Yasser

AU - Pathare, Anil

PY - 2013/3

Y1 - 2013/3

N2 - Iron overload is mainly responsible for the morbidity and mortality in patients with beta thalassemia major (TM). Our aim was to compare treatment outcomes with oral iron chelators, deferiprone (DFP), and deferasirox (DFX) in the first two decades on therapy. Seventy patients with TM (mean age ± SD, 7.9 ± 4.2; range 1.5-17 years) attending the pediatric day care unit for regular transfusional support were enrolled in this cross-sectional cohort study. The patients were treated either with DFP at the dose of 75-100 mg/kg/d in three divided doses after food or DFX at the dose of 25-40 mg/kg/d as single dose before food. Mean serum ferritin (±SD) was lower in patients below 10 years (n = 44) at 1283 (±600) ng/mL when compared with patients ≥10 years (n = 19) at 1546 (±589) ng/mL. There was no significant difference in mean serum ferritin (±SD) level in patients receiving DFP (1360 ± 589) versus DFX (1260 ± 641) in this cohort, P > 0.05. 67% of the patients had Vitamin D deficiency (

AB - Iron overload is mainly responsible for the morbidity and mortality in patients with beta thalassemia major (TM). Our aim was to compare treatment outcomes with oral iron chelators, deferiprone (DFP), and deferasirox (DFX) in the first two decades on therapy. Seventy patients with TM (mean age ± SD, 7.9 ± 4.2; range 1.5-17 years) attending the pediatric day care unit for regular transfusional support were enrolled in this cross-sectional cohort study. The patients were treated either with DFP at the dose of 75-100 mg/kg/d in three divided doses after food or DFX at the dose of 25-40 mg/kg/d as single dose before food. Mean serum ferritin (±SD) was lower in patients below 10 years (n = 44) at 1283 (±600) ng/mL when compared with patients ≥10 years (n = 19) at 1546 (±589) ng/mL. There was no significant difference in mean serum ferritin (±SD) level in patients receiving DFP (1360 ± 589) versus DFX (1260 ± 641) in this cohort, P > 0.05. 67% of the patients had Vitamin D deficiency (

KW - Beta thalassemia major

KW - Deferasirox

KW - Deferiprone

KW - Ferritin

KW - Iron overload

UR - http://www.scopus.com/inward/record.url?scp=84873887257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873887257&partnerID=8YFLogxK

U2 - 10.3109/08880018.2012.762568

DO - 10.3109/08880018.2012.762568

M3 - Article

C2 - 23363369

AN - SCOPUS:84873887257

VL - 30

SP - 104

EP - 112

JO - Pediatric Hematology and Oncology

JF - Pediatric Hematology and Oncology

SN - 0888-0018

IS - 2

ER -